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Background: Pre-eclampsia (PE) remains a disease of theories despite extensive research into its etiology. Alteration
in the production of vascular endothelial growth factor (VEGF), a biomarker of endothelial dysfunction, is associated
with pre-eclampsia although conflicting reports have been reported. The aim of the study was to determine and
compare maternal serum levels of VEGF among pre-eclamptics, normotensive non pregnant and pregnant women.
This was a cross-sectional study involving 100 women with pre-eclampsia, 102 women with normotensive
pregnancy and 75 normotensives who were not pregnant. The study was carried out at Korle Bu Teaching Hospital
(KBTH) from April to June in 2011. Basic socio-demographic and obstetric data were obtained by means of
structured questionnaire. Following venesection, about 5mls of blood was sampled from the participants for the
various tests. Enzyme Linked Immunosorbent Assay was used to determine the maternal serum levels of free VEGF.
Data analysis was performed using SPSS version 20.
Results: Significant reduction in median serum levels of free VEGF was seen in both, normal pregnant [84.06 pg/ml
(IQR: 78.90–99.67)] and pre-eclamptic women [4.71 pg/ml, (IQR: 3.41–7.93)] compared to the non-pregnant (395.85 pg/
ml, IQR 234.93–625) with p < 0.001; the reduction was far greater in the pre-eclamptic group compared to that of
normotensive pregnant group (p < 0.001). Early-onset pre-eclampsia had significantly more severe reduction in free
VEGF levels (3.89, IQR: 2.60–5.67 pg/ml) compared to that of late onset PE (5.23, IQR: 3.78–16.97 pg/ml) with p<0.001
indicating a severer endothelial damage in former.
Conclusions: Endothelial dysfunction contributes significantly to the pathogenesis of pre-eclampsia as demonstrated
by profound decrease in maternal serum VEGF levels in PE compared to normotensive pregnancy and non-pregnancy
state. The pathophysiology of early-onset pre-eclampsia may be partly explained by marked reduction in free serum
VEGF levels with resultant severe endothelial dysfunction.
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Pre-eclampsia (PE) is a multi-system pregnancy specific
disorder, characterized by new onset of hypertension and
proteinuria developing after the gestational age of 20 weeks
[1–3]. It remains a major cause of both maternal and peri-
natal mortality and morbidity [1–4]. Maternal mortality in
PE is mostly due to major complications such as eclampsia,
cerebral hemorrhage and renal failure [3, 4]. Currently,
hypertensive disorders including pre-eclampsia are the* Correspondence: bonsaffoh@yahoo.com
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Pre-eclampsia remains a disease of theories despite
extensive research into its etiology as the exact cause
remains uncertain [1, 2]. Dysfunctional endothelium is
hypothesized to contribute significantly in the pathogen-
esis of pre-eclampsia. Alteration in the production of
VEGF, a biomarker of endothelial dysfunction, has been
associated with pre-eclampsia although conflicting of
increased, decrease and normal maternal serum VEGF
levels have been reported [6, 7]. Adequate knowledge
about the pathophysiologic role of VEGF in pre-eclampsia
is vital in devising appropriate screening tests to facilitate
early detection and treatment of the disease.le is distributed under the terms of the Creative Commons Attribution 4.0
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terations in maternal plasma concentrations of vascular
endothelial growth factor (VEGF), and other related
growth factors and their receptors. VEGF has been im-
plicated in pre-eclampsia because it contributes signifi-
cantly to physiological vasculogenesis and vascular
permeability [7]. VEGF is known to stimulate the pro-
duction of nitric oxide which is a potent vasodilator as-
sociated with gestational vasodilation characteristic of
normal pregnancies. In addition, there is genetic evi-
dence from VEGF conditional knockout mice that inter-
ference with VEGF signaling in the kidneys leads to
clinical features of PE such as proteinuria and glomeru-
lar endotheliosis [8]. The major important attributes of
VEGF include stimulation of angiogenesis and promo-
tion vasodilation by stimulating the production of nitric
oxide and prostacyclin which are important signaling
molecules [7, 8].
In Ghana and most parts of Africa, there is limited
data regarding the contribution of VEGF to the patho-
physiology of PE indicating a significant gap in know-
ledge in our indigenous setting. This study aimed at
determining whether or not endothelial dysfunction has
a significant contribution in the pathogenesis of pre-
eclampsia by comparing maternal serum levels of free
VEGF in normotensive non-pregnant, normotensive
pregnant and pre-eclamptic women.
Methods
This was a cross-sectional study conducted at the De-
partment of Obstetrics and Gynecology of the KBTH in
Accra from April to June, 2011. Korle Bu Teaching Hos-
pital is a tertiary centre and the biggest teaching hospital
in Ghana with a total bed capacity of 1600 with about
12,000 deliveries per year. It is a training institution for
the College of Health Sciences of the University of
Ghana. Antenatal care is offered on a daily basis from
Monday to Friday at KBTH and pregnant women are
usually seen after every four weeks until 28 weeks, fort-
nightly until 36 weeks and then weekly till delivery.
The study protocol was approved by the Ethical and
Protocol Review Committee of the School of Medicine
and Dentistry, of the University of Ghana. All the study
participants provided informed consent. Study partici-
pants who could not give informed consent were ex-
cluded from the study and the informed consent was
not obtained from next of kins, caretakers or guardians.
In this study, pre-eclampsia was defined as new onset of
hypertension (systolic blood pressure of 140 mm Hg or
more and/or diastolic blood pressure of 90 mm Hg or
more) and proteinuria after the gestational age of
20 weeks [3]. Early- and late-onset pre-eclampsia were
defined as PE that develops before and at or after gesta-
tional age of 34 weeks respectively [9, 10]. Mild andsevere pre-eclampsia were defined as maternal systolic
blood pressure of 160 mm Hg or more and/or diastolic
blood pressure of 110 mm Hg or more on two occasions
at least 6 h apart [3]. Proteinuria was determined using
the semi-quantitative dipstick testing and significant
proteinuria was defined as the presence of urine proteins
of 1+ or more corresponding to 0.3 g or more of protein
in a 24-h urine specimen [3].
The detailed methodology has been published elsewhere
[11]. Briefly, the study participants were recruited using
systematic random sampling. Structured questionnaire
was used to collect data on basic demographic and obstet-
ric characteristics of the study participants (Table 1).
Other necessary data about the participants such as blood
pressure at diagnosis and delivery, birth weights of the ba-
bies and gestational ages at delivery were retrieved from
the medical records. The study participants were given
identification numbers recorded in a log book which was
kept securely during the study period. All the data ob-
tained were also kept securely and the study participants
were identified only by the study identification number
and not by their names.
Blood sampling
Venous blood samples were taken from the antecubital
fossae of the study participant for study purposes after
application of a tourniquet. Blood samples were obtained
upon presentation from all patients and controls. In pre-
eclamptic patients, the blood samples were obtained at
the time of diagnosis prior to the commencement of any
antihypertensive treatment including the use of magne-
sium sulphate. In the normotensive non pregnant
women, the blood samples were collected in during the
follicular phase of the menstrual cycle and were uniform
for all such participants. Non pregnant women who had
chronic medical conditions such as hypertension, sickle
cell disease, asthma, cardiac disease and those on any
hormonal medications such as contraceptives were ex-
cluded from the study. The blood samples were col-
lected into plain sterile test tubes and no inhibitors were
added to samples at the time of collection. The blood
sample was centrifuged for 15 min at 1000 × g within
one hour of collection and the serum was stored in a
fridge at −80 °C before the laboratory assays were car-
ried out. Repeated freeze-thaw cycles were avoided.
Measurement of VEGF levels
Human VEGF ELISA test kit (Quantikine, USA) was
used to determine serum levels of VEGF. The VEGF
assay was carried out strictly according to the instruc-
tions of the manufacturers. Recombinant human VEGF
standard in a 2-fold serial dilution from 3000 pg/ml to
31.25 pg/ml using 1.0 mL of calibrator diluent RD6U
was employed. 100uL of standard, control and serum












<20 1 (1.3) 5 (4.9) 2 (2.0) 8 (2.9)
20–34 51 (68.0) 85 (83.3) 69 (69.0) 205 (74.0)
≥35 23 (30.7) 12 (11.8) 29 (29.0) 64 (23.1)
Parity
0 38 (50.7) 35 (34.3) 61 (61.0) 134 (48.4)
1 21 (28.0) 34 (33.3) 20 (20.0) 75 (27.1)
2≥ 16 (21.3) 33 (32.4) 19 (19.0) 68 (24.5)
GA at delivery
<34 - 3 (0.3) 10 (10.0) 13 (6.4)
34–36 - 5 (0.5) 44 (44.0) 49 (24.3)
≥37 - 94 (92.2) 46 (46.0) 140 (69.3)
GA Gestational age in weeks
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at room temperature. After a 4 times washing step,
200 μL of VEGF Conjugate (polyclonal antibody against
VEGF conjugated to horseradish peroxidase) was added
to each well and the plates were incubated for 2 hour at
room temperature. The plates were then washed 5 times
and developed with 200 μL/well of 3,3′,5,5′-Tetra-
methylbenzidine TMB (4390A, Kem-En-Tec Diagnostics,
USA) substrate for 25 min. The reaction was stopped
using a sulfuric acid stop solution and optical densities
read at 450 nm. The mean absorbance for each set of
duplicate standards, controls and samples were then cal-
culated, and the average zero standard optical density
was subtracted to obtain the required values.
Statistical analyses
Data analysis was performed with SPSS version 20
(Microsoft company, USA). Descriptive analysis was per-
formed and the results were presented in percentages (for
categorical data), mean ± standard deviation (for continu-
ous data). The median serum levels of VEGF between the
normotensive non-pregnant, normotensive pregnant and
pre-eclamptic women were also compared using non-
parametric Kruskal-Wallis test and results presented using
box plots. Post hoc analysis was then performed using the
Bonferroni’s test to determine the specific differences
following the Kruskal-Wallis test. The pre-eclamptic group
was, further, sub-classified into early- and late-onset pre-
eclampsia. The maternal age, systolic and diastolic blood
pressure at diagnosis and delivery and birth weight were
compared between the two groups using independent stu-
dent t-test and the results were presented in means ±
standard deviation. Median serum levels of VEGF between
early and late –onset pre-eclamptic women were alsocompared using non-parametric Mann–Whitney test and
results presented using box plots. Also, the median serum
levels of VEGF between mild and severe pre-eclamptic
based on diastolic, systolic blood pressures or both com-
pared using non-parametric Mann–Whitney test. A p-
value of less than 0.05 was interpreted as statistically sig-
nificant at 95% confidence interval.
Results
The study included 100 women with pre-eclampsia, 102
normotensive pregnant (control group 1) and 75 normo-
tensive women who were not pregnant (control group 2)
resulting in a total of 277 participants. Table 1 indicates
the characteristics of the study participants. Significant
differences were found between the pre-eclamptic and
normotensive pregnant women in terms of the mean
systolic and diastolic at the time of recruitement
(p<0.001).
Most (74%) of the study participants were between 20 to
34 age group. Regarding parity distribution, 61%, 20% and
19% of the pre-eclamptics were nulliparous, primiparous
and multiparous respectively. At the time of diagnosis, 35
(35%), 44 (44%) and 21 (21%) of the pre-eclamptics had
gestational ages of <34 weeks, between 34 to 36 and
≥37 weeks respectively. There were 35 (35%) and 65 (65%)
women with early- and late onset PE respectively. No statis-
tically significant differences were found with respect to
age, parity between the two groups. There were significant
differences between early- and late onset PE with respect to
birth weight, gestational age at diagnosis and delivery, blood
pressures at diagnosis and delivery (Table 2). Also, signifi-
cant differences were determined between the median
serum VEGF levels in normotensive non-pregnant,
pre-eclamptic and normotensive pregnant women with
Table 2 Demographic and clinical characteristics women with
early- and late-onset pre-eclampsia
Variable Early onset PE Late onset PE P-value
N = 35 N = 65
Age (years) 30.66 ± 5.75 29.09 ± 5.30 0.175
GA at diagnosis (weeks) 30.74 ± 2.12 35.77 ± 1.49 <0.001b
Ga at Delivery (weeks) 34.29 ± 2.28 36.80 ± 1.20 <0.001b
SBP at diagnosis (mmHg) 175.43 ± 28.84 160.42 ± 12.58 <0.001b
DBP at diagnosis (mmHg) 110.86 ± 12.46 103.82 ± 10.58 0.004a
Birth weight (g) 1862.86 ± 665.57 2723.23 ± 544.26 <0.001b
SBP at delivery (mmHg) 186.97 ± 17.32 174.15 ± 14.88 <0.001b
DBP at delivery (mmHg) 115.09 ± 9.80 110.00 ± 9.52 0.013a
DBP Diastolic blood pressure, SBP Systolic blood pressure, PE Pre-eclampsia, GA
Gestational age
aSignificant; bvery Significant; All the values in the Table are presented
in mean ± SD
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pregnant, pre-eclamptic and normal pregnant women are
395.85 pg/ml (IQR: 234.93–625), 4.71 pg/ml (IQR: 3.41–
7.93) and 84.06 pg/ml (IQR: 78.90–99.67) respectively (p
< 0.001) (Fig. 1). Posthoc analysis using the Mann Whit-
ney test showed significant differences in the median
serum VEGF levels between pre-eclampsia and normoten-
sive pregnancy (p < 0.001), eclampsia and normotensive
pregnancy (p < 0.001) and normotensive pregnancy and
non-pregnancy states (p < 0.001). Maternal serum median
VEGF levels were significantly lower in early-onset PE
(3.89, IQR 2.60–5.67 pg/ml) compared to that of late-
onset disease (5.23, IQR 3.78–16.97 pg/ml) with p<0.001
(Fig. 2). There was a significant difference in birth weight
of the neonates (in grams) between the normotensive
pregnant (3197.06 ± 538.92) and pre-eclamptic women
(2422.10 ± 716.76) with a p-value less than 0.001.Fig. 1 Maternal serum levels of free VEGF in pre-eclampsia, normotensive pMild and severe pre-eclampsia occurred in 47% and
53% of pre-eclamptics respectively when classified using
diastolic pressure only, 37% and 63% respectively when
classified using systolic pressure only, and 24% and 76%
respectively when classified based on both diastolic and
systolic pressures combined Table 3. There were no sig-
nificant differences across the various categories regard-
ing mean gestational age at diagnosis and delivery.
However, there were significant differences between the
two disease entities across the various categories of
classification with respect to the systolic and diastolic
blood pressures. Generally, there were no significant
differences between severe and mild disease across the
various categorizations with respect to the maternal
serum median levels of vascular endothelial growth
factor (Table 3). Among the pre-eclamptics, proteinuria
occurred in 26 (26.0%), 54 (54.0%), 17 (17.0%) and 3
(3.0%) women in severity order of +1, +2, +3 and +4 re-
spectively. There was no statistically significant differ-
ence (p = 0.281) between the maternal serum VEGF
levels and the severity of proteinuria in women with pre-
eclampsia (Fig. 3). Among women with early and late
onset PE, +1 proteinuria occurred in 8 (22.9%) and 18
(27.7%), +2 proteinuria occurred in 20 (57.1%) and 34
(52.3%), +3 proteinuria in 6 (17.1%) and 11 (16.9%), +4
proteinuria in 1 (2.9%) and 2 (1.5%) women respectively.
Discussion
The contribution of vascular endothelial growth factor
(VEGF) in pathophysiology of pre-eclampsia has re-
ceived huge attention recently although conflicting re-
ports has been reported in previous studies [6, 7, 12].
This study has demonstrated a significant reduction in
maternal serum free VEGF levels in both normotensive
pregnancy and pre-eclampsia compared to the normo-
tensive non-pregnant state. However, the reduction inregnancy, and non-pregnant state
Fig. 2 Maternal serum levels of free VEGF in early- and late-onset pre-eclampsia
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nificantly far greater than that of the normal pregnancy
(p<0.001). This shows that although there was significant
decrease in serum VEGF levels in normal pregnancy as
well, it did not probably reach the critical threshold that
could cause significant endothelial dysfunction necessary
to result in clinical evidence of pre-eclampsia.
The results obtained in our study agree with other
reports that have demonstrated severe reductions in
maternal serum VEGF levels in PE [13–15]. The marked
reduction in serum VEGF levels determined in associ-
ation with pre-eclampsia could be attributed to high
soluble fms-like tyrosine kinase-1 (sflt-1) levels. Soluble
flt-1 usually binds to and inhibits multiple pro-





Variable Mild PE Severe PE P -value Mild PE
N = 47 N = 53 N = 37
Age
(years)
29.68 ± 5.32 29.60 ± 5.67 0.944 30.73 ± 5.39
DBP
(mmHg)
96.77 ± 5.92 114.72 ± 8.68 <0.001 100.76 ± 8.0
SBP
(mmHg)
156.74 ± 12.02 173.58 ± 23.95 <0.001 147.49 ± 5.40
GA1 34.43 ± 2.93 33.64 ± 2.96 0.187 33.78 ± 3.21
GA 2 36.32 ± 1.64 35.57 ± 2.30 0.066 35.95 ± 1.81
Birth
weight (g)




4.84 (3.44–16.97) 4.60 (3.40–6.48) 0.227 4.68 (3.40–6.70)
PE pre-eclampsia, GA1 gestational age at diagnosis, GA2 gestational age at delivery,
at diagnosisfactor (PIGF) by preventing their communication with
the respective endothelial cell receptors [16]. The
physiological effects of VEGF are mediated via its bind-
ing to two high-affinity receptor tyrosine kinases which
are selectively expressed on the surface of the vascular
endothelial cell [6, 12, 13]. Soluble flt-1 is a splice variant
of flt-1 having the extracellular domain but lacking both
the transmembrane and cytoplasmic domains which
were excised post-transcriptionally. Soluble flt-1 acts as
a potent antagonist by binding to VEGF and inhibits its
biologic activity [16].
In this study, maternal serum free VEGF levels were
found to be markedly lower in the early compared to the
late onset PE (p<0.001) buttressing the fact that early




Severe PE P -value Mild PE Severe PE P -value
N = 63 N = 24 N = 76
29.54 ± 5.47 0.128 31.75 ± 4.55 28.97 ± 5.61 0.030
109.52 ± 12.37 <0.001 95.75 ± 4.98 109.61 ± 11.25 <0.001
176.35 ± 19.29 <0.001 146.96 ± 6.13 171.58 ± 20.53 <0.001
34.14 ± 2.82 0.561 33.54 ± 3.48 34.16 ± 2.79 0.377
35.90 ± 2.18 0.923 36.08 ± 1.95 35.87 ± 2.08 0.656
2452.38 ± 739.14 0.584 2387.92 ± 751.83 2432.89 ± 710.14 0.790
4.73 (3.77–13.18) 0.689 2.68 (2.98–4.64) 4.71 (3.70–7.93) 0.654
DBP diastolic blood pressure at diagnosis, SBP systolic blood pressure
Fig. 3 Maternal serum VEGF levels and severity of proteinuria in pre-eclampsia
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eclampsia, placental cells secrete high levels of soluble
isoform of flt-1 (an antiangiogenic factor) which inter-
acts and neutralizes the effects of VEGF and PIGF [9].
The finding of markedly reduced levels of free VEGF in
early onset pre-eclampsia is consistent with other re-
ports and this suggests marked endothelial dysfunction
and dysregulation manifesting as severe hypertension
and proteinuria. This is evidenced by the significantly
high blood pressures recorded in early compared to late
onset PE. The higher the serum sflt-1 levels, the lower
the bioavailable VEGF levels and the severer the endo-
thelial dysfunction [17] resulting in severer clinical
manifestation. The markedly reduced free VEGF levels
determined in early onset PE points to the possibility of
different pathophysiological mechanisms and clinical
presentations.
We did not measure maternal serum levels of sflt-1 in
association with VEGF, however, there is enough evidence
from previous studies demonstrating that sflt-1 levels are
significantly elevated in pre-eclampsia causing marked re-
duction in the circulating levels of free VEGF [13, 15, 17].
Increased soluble flt-1 levels produces hypertension, pro-
teinuria and glomerular endotheliosis in both pregnant
and non-pregnant rats and these features also characterize
pre-eclampsia [18]. This strongly suggests that significant
decrease in free VEGF levels resulting in endothelial dys-
function is implicated in the pathogenesis of pre-
eclampsia. However, other studies have demonstrated that
maternal serum free VEGF levels may be increased, nor-
mal or decreased in uncomplicated pregnancy [12, 19, 20].
The fact that maternal serum levels of sflt-1 were not
measured concurrently with VEGF is considered a limita-
tion of this study since it would have provided moreinsight into the relativity of these factors to endothelial
damage in pre-eclampsia.
However, there were no significant differences between
severe and mild disease with respect to the median mater-
nal vascular endothelial growth factor levels when pre-
eclampsia was categorized based on diastolic, systolic
blood pressure values or both (Table 3). These findings
might partly be due to the fact that clinical disease severity
based on the blood pressure readings alone might not cor-
relate well with the severity of endothelial functional and
morphological injury in pre-eclampsia. Therefore, clinical
decision making based on the severity of the blood pres-
sure alone, especially regarding termination of pregnancy
might not always be justifiable. This buttresses the need
for biochemical monitoring alongside clinical features in
the management of pre-eclampsia. However, there was a
tendency of significantly lower VEGF levels in severe com-
pared when pre-eclampsia categorized based on diastolic
blood pressure alone although the difference did not reach
statistical significance.
The conflicting results as demonstrated by other re-
searchers with respect to maternal serum VEGF levels in
normotensive pregnancy and pre-eclampsia could prob-
ably be attributed to different gestational ages at which
the women were studied [19] as well as differences in
methodology. In this study, all the gravid women were
studied at or after the gestational age of 28 weeks and
therefore there is limited confounding effect that could
have been introduced by differences in gestational age.
The markedly reduced serum VEGF levels in pre-
eclampsia are not unexpected because hypertension and
proteinuria are the main signs of VEGF deficiency.
Maynard and colleagues determined that administra-
tion of exogenous VEGF therapy might restore normal
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therapy using pro-angiogenic analogues might be rele-
vant in the management of pre-eclampsia by improving
vascular endothelial function. The use of nicotine may
be clinically beneficial in the treatment of pre-eclampsia
since it is associated with stimulation of angiogenesis
[14] but this is not recommended in pre-eclampsia as it
is associated with intrauterine growth restriction which
is also a recognized complication of pre-eclampsia.
However, it has been suggested that short term use of
nicotine in the management of severe pre-eclampsia
might be helpful since it is associated with reduction in
sFlt1 levels in humans [7]. Moreover, lower incidence of
pre-eclampsia has been shown in individuals who smoke
due to reduced serum sflt-1 [21].
Intrauterine growth restriction (IUGR) is a recognized
complication of pre-eclampsia and the two conditions
share many clinical and pathologic features [7].
Alteration in angiogenic factors in IUGR without pre-
eclampsia is less pronounced than in pre-eclampsia.
Although IUGR is frequently associated with early onset
PE it can also occur without pre-eclampsia [7]. The
pathophysiological mechanisms of these two related
conditions are associated with the failure of the tropho-
blasts to achieve deeper invasion of the maternal spiral
arteries during early pregnancy [22]. The mean birth
weight and gestational age at delivery determined in our
study were significantly lower among women with pre-
eclampsia compared to normotensive pregnancy women
(Table 1). Similarly, early onset PE delivered at an earlier
gestational age with significantly smaller mean birth
weight compared late onset disease (Table 2). Fetal
growth restriction is a major complication of pre-
eclampsia [3, 7] and it might be responsible for the
lower birth weights recorded in PE and especially in the
early onset type.
However, significant elevation of VEGF levels in pre-
eclampsia has also been reported [20]. The explanation
for the increase in VEGF was its association with ex-
travasation of plasma proteins and proteinuria. This par-
ticular characteristic of VEGF is related to its ability to
regulate endothelial cell function and vascular perme-
ability at microcirculation level [20].
The strength of this study revolves around the large
numbers of participants involved and the fact that it is the
first study in Ghana relating the pathophysiology of pre-
eclampsia to VEGF. However, the study has a number of
limitations and this include the determination of VEGF in
serum rather than plasma which is more reliable. There is
evidence that platelets and leukocytes release VEGF during
blood clotting associated with the use of serum [23] and
this might have influenced the result obtained. Also, spe-
cific inhibitors could prevent the release of VEGF from
platelets and leukocytes in the serum [23] but none of suchinhibitors were added to the samples. Another limitation is
associated with the use of semi-quantitative method in the
determination of proteinuria compared with the 24 h urine
collection method which is more reproducible.
Conclusions
This study has demonstrated marked reduction in mater-
nal serum bioavailable VEGF levels in pre-eclampsia com-
pared to normotensive pregnancy suggesting marked
vascular endothelial cell dysfunction resulting in general-
ized vasoconstriction, hypertension and proteinuria. This
might be associated with the lower birth weight recorded
in the pre-eclamptic group as a part of intrauterine growth
restriction which commonly complicates pre-eclampsia.
The reduction in serum free VEGF levels was markedly
more severe in early-onset pre-eclampsia coupled with
severe low birth weight compared to late onset disease in-
dicating a severer endothelial injury in the former.
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